Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**PhytoTech Medical Limited**
ABN	**601 230 417**

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Benad Goldwasser
Date of appointment	28 January 2015

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
	Nil

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Consultancy Agreement
Nature of interest	Party to the Agreement
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	Under the terms of the agreement, subject to shareholder approval, Mr Goldwasser or his nominee is entitled to be granted 1,500,000 unquoted options to acquire fully paid ordinary shares in the capital of PYL exercisable at $0.20 each (Options). The Options shall vest over a period of 3 years, such that 1/12 of the Options shall vest on the end of each three (3) months period following his appointment.

+ See chapter 19 for defined terms.